136 related articles for article (PubMed ID: 21187506)
1. Efficacy of sunitinib in patients with renal cell carcinoma with bone metastases.
Paule B; Brion N
Anticancer Res; 2010 Dec; 30(12):5165-8. PubMed ID: 21187506
[TBL] [Abstract][Full Text] [Related]
2. Intermittent treatment with sunitinib may achieve complete response in metastatic renal cell carcinoma.
Aksu G; Ensaroglu F; Dolasik I; Temiz S; Halis H; Sener SY; Kaya A; Uygun K
J BUON; 2010; 15(4):798-9. PubMed ID: 21229650
[No Abstract] [Full Text] [Related]
3. Bisphosphonates and vascular endothelial growth factor-targeted drugs in the treatment of patients with renal cell carcinoma metastatic to bone.
Vrdoljak E; Rini B; Schmidinger M; Omrčen T; Torday L; Szczylik C; Sella A
Anticancer Drugs; 2013 Jun; 24(5):431-40. PubMed ID: 23511427
[TBL] [Abstract][Full Text] [Related]
4. [Efficacy of Sunitinib Rechallenge in Metastatic Renal Cell Carcinoma : A Case Report].
Yoshinaga A; Kamata S
Hinyokika Kiyo; 2015 May; 61(5):201-5. PubMed ID: 26087822
[TBL] [Abstract][Full Text] [Related]
5. Does the onset of bone metastasis in sunitinib-treated renal cell carcinoma patients impact the overall survival?
Ivanyi P; Koenig J; Trummer A; Busch JF; Seidel C; Reuter CW; Ganser A; Grünwald V
World J Urol; 2016 Jul; 34(7):909-15. PubMed ID: 26586475
[TBL] [Abstract][Full Text] [Related]
6. Bisphosphonates in patients with renal cell carcinoma and bone metastases: a sunitinib global expanded-access trial subanalysis.
Vrdoljak E; Gore M; Leyman S; Szczylik C; Kharkevich G; Schöffski P; Torday L; Mardiak J; Zhang K; Sajben P; Sella A
Future Oncol; 2015; 11(20):2831-40. PubMed ID: 26118456
[TBL] [Abstract][Full Text] [Related]
7. Correlation of c-Met Expression and Outcome in Patients With Renal Cell Carcinoma Treated With Sunitinib.
Peltola KJ; Penttilä P; Rautiola J; Joensuu H; Hänninen E; Ristimäki A; Bono P
Clin Genitourin Cancer; 2017 Aug; 15(4):487-494. PubMed ID: 28237182
[TBL] [Abstract][Full Text] [Related]
8. Sunitinib re-challenge in metastatic renal cell carcinoma treated sequentially with tyrosine kinase inhibitors and everolimus.
Paule B; Brion N
Anticancer Res; 2011 Oct; 31(10):3507-10. PubMed ID: 21965770
[TBL] [Abstract][Full Text] [Related]
9. Antitumor effect of sunitinib against skeletal metastatic renal cell carcinoma through inhibition of osteoclast function.
Maita S; Yuasa T; Tsuchiya N; Mitobe Y; Narita S; Horikawa Y; Hatake K; Fukui I; Kimura S; Maekawa T; Habuchi T
Int J Cancer; 2012 Feb; 130(3):677-84. PubMed ID: 21387300
[TBL] [Abstract][Full Text] [Related]
10. Sunitinib for metastatic renal cell carcinoma.
Mukherji D; Larkin J; Pickering L
Future Oncol; 2010 Sep; 6(9):1377-85. PubMed ID: 20919823
[TBL] [Abstract][Full Text] [Related]
11. Successful sunitinib treatment of metastatic renal cell carcinoma in a patient with end stage renal disease on hemodialysis.
Park CY
Anticancer Drugs; 2009 Oct; 20(9):848-9. PubMed ID: 19644356
[TBL] [Abstract][Full Text] [Related]
12. Oligometastatic state predicts a favorable outcome for renal cell carcinoma patients with bone metastasis under the treatment of sunitinib.
Lu X; Gu W; Zhang H; Zhu Y; Shi G; Ye D
Oncotarget; 2016 May; 7(18):26879-87. PubMed ID: 27058898
[TBL] [Abstract][Full Text] [Related]
13. Sunitinib in metastatic renal cell carcinoma patients with brain metastases.
Gore ME; Hariharan S; Porta C; Bracarda S; Hawkins R; Bjarnason GA; Oudard S; Lee SH; Carteni G; Nieto A; Yuan J; Szczylik C
Cancer; 2011 Feb; 117(3):501-9. PubMed ID: 20862748
[TBL] [Abstract][Full Text] [Related]
14. Quality of life in patients with metastatic renal cell carcinoma treated with sunitinib or interferon alfa: results from a phase III randomized trial.
Cella D; Li JZ; Cappelleri JC; Bushmakin A; Charbonneau C; Kim ST; Chen I; Motzer RJ
J Clin Oncol; 2008 Aug; 26(22):3763-9. PubMed ID: 18669464
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of sunitinib in metastatic renal cell carcinoma.
Purmonen TT
Expert Rev Pharmacoecon Outcomes Res; 2011 Aug; 11(4):383-93. PubMed ID: 21831017
[TBL] [Abstract][Full Text] [Related]
16. Current evidence and the evolving role of sunitinib in the management of renal cell carcinoma.
Noronha V; Joshi A; Bakshi G; Tongaonkar H; Prabhash K
Indian J Cancer; 2016; 53(1):102-8. PubMed ID: 27146754
[TBL] [Abstract][Full Text] [Related]
17. Sunitinib (Sutent): a novel agent for the treatment of metastatic renal cell carcinoma.
Chouhan JD; Zamarripa DE; Lai PH; Oramasionwu CU; Grabinski JL
J Oncol Pharm Pract; 2007 Mar; 13(1):5-15. PubMed ID: 17621562
[TBL] [Abstract][Full Text] [Related]
18. A phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma: insights into the treatment, efficacy and safety.
Uemura H; Shinohara N; Yuasa T; Tomita Y; Fujimoto H; Niwakawa M; Mugiya S; Miki T; Nonomura N; Takahashi M; Hasegawa Y; Agata N; Houk B; Naito S; Akaza H
Jpn J Clin Oncol; 2010 Mar; 40(3):194-202. PubMed ID: 19897852
[TBL] [Abstract][Full Text] [Related]
19. [Impact of immunotherapy in metastatic kidney cancer in Germany after introduction of new target therapy--results of a telephone survey of the German Society of Immuno- and Targeted Therapy (DGFIT)].
Siebels M; Staehler M; Hegele A; Varga Z; Oberneder R; Doehn C; Heinzer H;
Aktuelle Urol; 2010 Mar; 41(2):122-30. PubMed ID: 19937556
[TBL] [Abstract][Full Text] [Related]
20. Complete pathological response after sequential therapy with sunitinib and radiotherapy for metastatic clear cell renal carcinoma.
Venton G; Ducournau A; Gross E; Lechevallier E; Rochwerger A; Curvale G; Zink JV; Salas S; Deville JL
Anticancer Res; 2012 Feb; 32(2):701-5. PubMed ID: 22287766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]